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Abstract  
 
The NLST demonstrated that individuals assigned to the LDCT screening arm had a 20% 
lower mortality than those who were assigned to the conventional chest radiography. The 
NLST was thoroughly analyzed by the US Preventive Task Force on CT Screening and they 
recommended that lung cancer screening should be implemented.  
 
A number of other countries have also recommended implementation, whilst others are 
awaiting the outcome of the NELSON Trial. However, recommendations for the management 
of CT screen detected nodules has only recently had any clarity.   The management of CT 
detected nodules in the NLST was based on the identification and reporting of 4mm diameter 
nodules found on the CT screens but there was no NLST radiology protocol in place for the 
management of nodules.   
 
The use of volumetric analysis is not routinely used in the USA and there is still a reliance on 
utilising the CT nodule diameter as the management parameter. The first pulmonary risk 
model was developed by the Canadians, utilising data sets from the Pan-Canadian Early 
detection of Lung cancer (PanCan) and validated in the chemoprevention trial dataset at the 
British Columbian Agency. This Canadian model, known as the Brock Model, is currently 
available and has been integrated into the British Thoracic Society guidelines on the 
management of pulmonary nodules. 
 
The American College of Radiology setup a Lung Cancer Screening Committee subgroup on 
Lung-RADS, to standardize lung cancer screening CT reporting and provide management 
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recommendations. However, it has been recommended that the LungRADS system should be 
revised as the system as it has never been studied in a prospective fashion. 
 
The NELSON trial introduced a third screening test, the “indeterminate” screening test result, 
this was done with the aim to reduce the false-positives CT screening results and also utilized 
by the UKLS trial successfully. On comparing the radiological CT screen volumetric and 
diameter based protocols in the NELSON trial, the sensitivity and negative predictive value 
appeared to be comparable, however a higher specificity and positive predictive value was 
found for the volume-based protocols, thus confirming the advantage of utilising the 
volumetric approach over diameter. 
The British Thoracic Society (BTS) has undertaken an indepth piece of work developing 
guidelines on the management of pulmonary nodules, utilising the wealth of data published by 
the NELSON team and support the use of volumetric analysis for the management of 
pulmonary nodules.   
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The use of low dose CT (LDCT) for early lung cancer detection in high risk individuals has 
progressed from the first publication by Henschke et al. (1), through to the National Lung 
Cancer Screening trial (NLST) in 2011 (2), to the current data from the NELSON trial on the 
management of small pulmonary nodules. The NLST demonstrated that individuals assigned 
to the LDCT screening arm had a 20% lower mortality than those who were assigned to the 
conventional chest radiography. The current status of lung cancer screening trials has been 
extensively reviewed over the past three years, demonstrating the enormous strides in the 
management of lung cancer screening (3-6).  
 
Clearly the stage has been set in the USA for the implementation of lung cancer screening 
based on the NLST trial publication and also on the recommendation from the US Preventive 
Services Task Forces (USPSTF) (7) on lung cancer screening, resulting in the agreed funding 
from March 2016 by the Center for Medicare (8)and Medicaid (CMS). The USPSTF 
recommended annual screening for lung cancer in the 55-80 age group who have a 30 pack 
year smoking history and were either current smokers or have quit within the last 15 years. The 
independent review set up by the USPSTF modelled screening policies and investigated the 
long-term harms and benefits of lung cancer screening. The USPSTF have indicated that the 
parameters for selection should be review in time together with the management of these 
patients. 
 
We currently await the publication of the NELSON trial, which will provide valuable 
information on mortality and cost effectiveness, from the only fully powered European trial. 
However, all of the main CT screening trials have consistently demonstrated that early Stage 
disease is one of the core findings, with 81% from International Early Lung Cancer Detection 
Program (IELCAP), 63% from NLST, 73% from NELSON and 67% from the (United 
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Kingdom Lung Screening (UKLS) trial (Table 1), compared to the expected ~ 15%. Its also of 
note that a number of pilot European CT screening trials have provided an indepth insight into 
the management of CT detected nodules. 
 
The management of CT detected nodules in the NLST was based on the identification and 
reporting of 4mm diameter nodules found on the CT screens but there was no NLST radiology 
protocol in place for the management of nodules. Clearly, the early work undertake by IELCAP 
initiated the debate on utilising volumetric measurements for the management of small CT 
detected nodules. This work has been further developed by the NELSON group and latterly 
validated by the UKLS trial. 
 
The use of volumetric analysis is not routinely used in the USA and there is still a reliance on 
utilising the CT nodule diameter as the management parameter. The Canadian Pulmonary Risk 
model was developed utilising data sets from the Pan-Canadian Early detection of Lung cancer 
(PanCan) and validated in the chemoprevention trial dataset at the British Columbian Agency 
(BCCA) (9).  
 
Characterisation of nodules is well described within the PanCan risk model publication 
included a range of imaging parameters including speculation, which was found to be a major 
predictor in the PanCan data set, however, was not confirmed within the BCCA, as this data 
was not collected. The authors went on to develop parsimonious and full models with and 
without nodule spiculation. The model’s discrimination i.e. a measure of how well such model 
can separate diseased from non-diseased individuals is most often measured using the area 
under the receiver characteristic (ROC) curve or c-statistic (10). Halligan et al., has identified 
problems with ROC and argued that it depends on the method used for curve fitting and does 
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not account for prevalence or different misclassification costs arising from false-negative and 
false-positive diagnoses (11). Other methods and metrics of the performance of prediction 
models, such as the net benefit, have been proposed based on the change in sensitivity and 
specificity at clinical relevant thresholds (12). A major strength of this model is that it does not 
solely rely on ROC because  comparison of the models with and without spiculation showed 
no significant differences in AUC but the net re-classification between the two models did 
suggest that spiculation could improve prediction. Net benefit incorporates estimates of 
prevalence and misclassification costs, and it is clinically interpretable since it reflects changes 
in correct and incorrect diagnoses when a new diagnostic test is introduced (11, 12). The take 
home message was that if a threshold of at least 5% risk of lung cancer is used in the 
parsimonious model including spiculation, the sensitivity, specificity, positive predicative 
value and negative predicative value were: 71.4 %, 95.5%, 18.4% and 99.6%. Thus, the model 
developed by McWilliams et al. can be used to accurately estimate the probability that lung 
nodules detected on baseline screening with low-dose CT scans are malignant. This model 
showed good accuracy for determining likelihood of malignancy in nodules detected on CT 
scans (13) . However In patients undergoing (fluorodeoxyglucose positron emission 
tomography- computed tomography) FDG PET–CT for nodule evaluation, the highest 
accuracy was seen in the Herder and co-workers risk model (14). 
 
Lung CT screening Reporting and Data System (Lung-RADSver1) was published in 2014 (15). 
The American College of Radiology setup a Lung Cancer Screening Committee subgroup on 
Lung-RADS, in order to have a quality assurance tool to standardize lung cancer screening CT 
reporting and also provide management recommendations. The rationale behind this initiative 
is the hope that it would assist in lung cancer screening CT nodule scan interpretations. 
However, when LungRADS performance was compared to the NLST screening trial data, 
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certain issues arose, even though NLST summary data was used to construct the LungRADS 
scores (16). The comparative performance indicated that LungRADS substantially reduced the 
false positive result rate and the sensitivity level decreased. Recently it has been recommended 
by Mehta et al. that the LungRADS system needs to be revised and faulted the system on the 
basis that it has never been studied in a prospective fashion. 
 
Li et al have recently analysed the size and growth of pulmonary nodules, as a consequence of 
‘rounding up’ methodology used in LungRADS. (17). The example given is if a nodule with 
an average diameter of 5.5 mm is reported as 6 mm diameter since 6 mm diameter is the current 
threshold for a positive result, further workup would be recommended for this nodule. Thus, 
rounding up to the nearest whole number increases the frequency of positive results which 
require further work-up before the next scheduled screening round. The authors also indicated 
another possible confusion, as to whether the length or the width is rounded up, which is not 
indicated in the LungRADS criteria. The authors concluded that with the move towards the 
utilisation of computer aided techniques, rounding up will be used less often, furthermore, the 
trend towards volumetric assessment of nodules, will result in a much more precise 
methodology.  
 
The NELSON trial introduced a third screening test, the indeterminate screening test result, 
this was done with the aim to reduce the false-positives CT screening results (18). The 
importance of this decision is seen in the low percentage of false positives found in the 
NELSON trial. Especially, when one looks at the impact of the false positive screening test, 
with potential unnecessary work-up and invasive procedures and the possibility of 
overtreatment and the extra anxiety for the patients 
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In the UKLS (19) a very clear definition was made for false positive tests as those requiring 
further diagnostic investigation more immediately than a repeat annual screen, but who 
subsequently did not have lung cancer. The proportion of false positive tests was provided in 
two ways, which allows an appreciation, in a patient-centered approach, of the variable impact 
on the subject in a trial or the patient in a programme. A “false positive” that mandates referral 
to the lung cancer multidisciplinary team (MDT) clinic will usually be associated with 
significant psychological distress, and additional invasive investigations with, in some cases, 
definitive treatment. An individual with a false positive as defined above is more likely to 
suffer harm than one defined in a different way; that is, those subjects who are recalled solely 
for further CT imaging to clarify the nature of a nodule. The latter is best termed “Interval 
Imaging Rate” and may, in screening programmes, merely mean continuing in the programme 
rather than referral to the MDT. For this reason, all category 3 lesions in the UKLS trial without 
cancer (or called indeterminate nodules) were reported separately as false positives warranting 
interval imaging (19).  
 
In the UKLS, the false positive rate was 3.6% whilst the Interval Imaging Rate was 23.2% 
amongst participants referred to MDT clinic. The NELSON trial reported their false positive 
rate in 2013 as 3.6% (20) . Both the UKLS and the NELSON utilised the indeterminate 
screening result whenever the participant received a repeat test within a period of three months, 
which was analysed by utilising volumetric analysis. A 25% increase in volume was considered 
as ‘nodule growth’ and the patient was then referred to the MDT for conventional clinical 
work-up. The advantage of utilising volumetric analysis is diagrammatically demonstrated in 
Figure 1. On comparing the radiological CT screen volumetric and diameter based protocols 
in the NELSON trial, the sensitivity and negative predictive value appeared to be comparable, 
however a higher specificity and positive predictive value was found for the volume-based 
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protocols (21) thus confirming the advantage of utilising the volumetric approach over 
diameter. 
The data discussed so far in this article relates to base line data with nodule follow-up, however, 
the trial data which is relevant for routine screening are on new and incidental nodules comes 
from the extensive work undertaken by the NELSON team.  NELSON calculated the risk of 
developing lung cancer based on the volume, volume based diameter in a large dataset of 
screened participants found to have non-calcified nodules and developed a probability table 
(Figure 2). It’s of note that the probability was not significantly different between the NELSON 
participants with nodules <100mm3 compared to those with no CT detected nodules in the trial 
(0.6% vs 0.4%). However, individuals with 100mm3 - 300mm3 nodal volume had a higher 
probability of developing lung cancer (2.4%) and were considered indeterminate with 
intermediate risk; whilst the participants with nodules greater than 300mm3 had a significantly 
greater risk compared to no nodules (16.9%) and thus had a very high probability of developing 
lung cancer (21). 
 
A very important message was provided on examining the NELSON volume doubling time 
data; the two year probability of developing lung cancer in patients with nodules measuring 
50mm3 -100mm3 (or 4-5mm diameter) was extremely low and did not significantly differ from 
patients with no CT scan detected nodules. This potentially opens up whether these individuals 
require yearly CT scans in a long term screening program and takes into account the harm and 
benefits for regular screening in such individuals; i.e. radiation exposure, psychological distress 
and cost effectiveness. 
 
New Pulmonary nodules at incident screens is now recognised as a clinical issue which has 
been analysed by Walters et al (22). NELSON registered 1222 new nodules in 787 participants. 
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Fifty lung cancers were found, representing 4% of all new solid nodules and 34 (68%) lung 
cancers were diagnosed at Stage I. the reported that the new nodules with < 27mm3, 27mm3 – 
206mm3, 206mm3 were classified as low (0.5%), Intermediate (3.1%) and high risk (16.9%) 
probability of developing lung cancer. The NELSON data showed that new solid nodules are 
detected at each screening round in 5-7% of patients and have a significant probability of being 
malignant, even if they are of a small size. These finding will have an impact on the way we 
develop our future screening guidelines.  
 
The British Thoracic Society (BTS) has undertaken an indepth piece of work developing 
guidelines on the management of pulmonary nodules (23) . This work has been based on 
extensive review of the literature and the utilisation of recent publication from a number of 
lung cancer CT screening trials and in the depth analysis of the data. A Guideline Development 
Group (GDG) was assembled utilising new research evidence, they have provided four 
management algorithms and the have included two malignancy prediction calculators (already 
discussed in this article), Figure 3. Furthermore, volumetry has been recommended by BTA as 
the preferred measurement method of CT detected nodules and they also provided 
recommendations for the management of nodules with extended volume doubling times. 
 
The BTS guidelines provide recommendation on the use of further imaging, and the use of 
PET-CT information which can be incorporated into pulmonary risk models, as well as advice 
on biopsy and the threshold for treatment without histological confirmation. Finally, BTS 
provided advice on the information which should be given to patients on the management of 
pulmonary nodules. 
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Clearly the field of pulmonary nodule management in CT screening continues to advance and 
with the recent publication on the risk of malignancy in new nodules which has highlighted the 
need to continuously refine the nodule management algorithms and that the new nodule risk 
data should be taken into account (24). 
 
Lung cancer screening is now a reality in the USA, covered by the Center for Medicare and 
Medicaid, however, Europe and the rest of the world have not as yet implemented national 
lung cancer CT screening programmes at the time of writing this article, as they await the 
publication of the NELSON trial, with its mortality and cost effectiveness data. There will be 
a range of challenges when each country starts to implement lung cancer screening 
programmes in Europe, which have already been identified (25) but we also need to ensure that 
the appropriate protocolled pulmonary nodule management pathways such as the BTS 
recommendations are agreed and put in place, in order that we achieve the greatest clinical 
impact from future lung cancer screening programmes. 
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Table 1 
 
 Participants 
in screening 
arm 
Screening 
Rounds 
No. Published 
CT detected 
Lung Cancers 
Stage IA & IB Lung 
Cancers 
Trial     
NLST 26,722 3 649 400 (61.6%) 
NELSON 7,915 4 209 148 (70.8%) 
DLST 2,052 5 69 47 (68.1%) 
ITALUNG 1,613 4 22 11 (50.0) 
DANTE 1,276 4 58 41 (70.7) 
MILD 1,190 10 20 18 (62.1%) 
 1,186 5 22 14 (70.0%) 
LUISI 2,029 4 22 18 (81.8%) 
UKLS  1,994 1 42 28 (67.8%) 
TOTAL 54,977 1-10 1,120 725 (64%) 
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Figure 1 
From:  Field JK, Oudkerk M, Pedersen JH, Duffy SW. Prospects for population screening 
and diagnosis of lung cancer. Lancet. 2013;382(9893):732-41. 
 
 
 
 
Legend: 
Upper figure: 
A volume growth of 26 % , defined as growth by NELSON  criteria, is hardly appreciable by 
diameter measurement (8 % diameter increase which is NO growth by current criteria) 
  
Legend figure below: 
A 25% diameter increase ie threshold for the current growth definition reflects almost a 
doubling in volume ( 95%). It reflects the insensitivity for growth of diameter measurement 
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Figure 2  
 
From:  Horeweg N, van Rosmalen J, Heuvelmans MA, van der Aalst CM, Vliegenthart R, 
Scholten ET, et al. Lung cancer probability in patients with CT-detected pulmonary nodules: 
a prespecified analysis of data from the NELSON trial of low-dose CT screening. Lancet 
Oncol. 2014;15(12):1332-41. 
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Figure 3 
 
Redrawn from: Callister ME, Baldwin DR, Akram AR, Barnard S, Cane P, Draffan J, et al. 
British Thoracic Society guidelines for the investigation and management of pulmonary 
nodules. Thorax. 2015;70 Suppl 2:ii1-ii54. 
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